- Home
- PSNYW vs CAPR Comparison
PSNYW vs CAPR Comparison
Compare PSNYW & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNYW
- CAPR
- Stock Information
- Founded
- PSNYW 2017
- CAPR 2005
- Country
- PSNYW Sweden
- CAPR United States
- Employees
- PSNYW N/A
- CAPR N/A
- Industry
- PSNYW Auto Manufacturing
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSNYW Consumer Discretionary
- CAPR Health Care
- Exchange
- PSNYW Nasdaq
- CAPR Nasdaq
- Market Cap
- PSNYW 362.3M
- CAPR 600.7M
- IPO Year
- PSNYW N/A
- CAPR N/A
- Fundamental
- Price
- PSNYW $0.16
- CAPR $6.34
- Analyst Decision
- PSNYW
- CAPR Strong Buy
- Analyst Count
- PSNYW 0
- CAPR 7
- Target Price
- PSNYW N/A
- CAPR $39.29
- AVG Volume (30 Days)
- PSNYW 42.8K
- CAPR 2.1M
- Earning Date
- PSNYW 03-06-2025
- CAPR 05-13-2025
- Dividend Yield
- PSNYW N/A
- CAPR N/A
- EPS Growth
- PSNYW N/A
- CAPR N/A
- EPS
- PSNYW N/A
- CAPR N/A
- Revenue
- PSNYW $2,046,740,000.00
- CAPR $22,270,465.00
- Revenue This Year
- PSNYW N/A
- CAPR $78.85
- Revenue Next Year
- PSNYW $79.49
- CAPR $157.99
- P/E Ratio
- PSNYW N/A
- CAPR N/A
- Revenue Growth
- PSNYW N/A
- CAPR N/A
- 52 Week Low
- PSNYW $0.09
- CAPR $3.52
- 52 Week High
- PSNYW $0.61
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- PSNYW 46.26
- CAPR 27.28
- Support Level
- PSNYW $0.16
- CAPR $12.16
- Resistance Level
- PSNYW $0.17
- CAPR $13.22
- Average True Range (ATR)
- PSNYW 0.01
- CAPR 1.22
- MACD
- PSNYW 0.00
- CAPR -0.65
- Stochastic Oscillator
- PSNYW 25.10
- CAPR 0.86
About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market-leading standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from USA.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.